Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 21 October, 2003

Xenova Group PLC

Research Update

Xenova Group PLC
21 October 2003

                                                           FOR IMMEDIATE RELEASE

Xenova Group plc

                 Xenova Statement on Imperial College Research
                    Into Novel Strategy for Treatment of Flu

Slough, UK, 21 October, 2003 - Xenova Group plc (NASDAQ NM: XNVA; London Stock
Exchange: XEN) notes that the following announcement was issued late yesterday
by Imperial College with respect to a research collaboration involving the
company's OX40 technology and its potential for the treatment of influenza.
OX40 is a platform technology capable of producing multiple drug candidates
targeting cancer, autoimmune and other diseases where the immune system is

David Oxlade, Chief Executive of Xenova, said, 'We are very encouraged by these
novel findings from the work conducted by Imperial College on our OX40 platform
technology.  The demonstration in pre-clinical studies that down-regulation of
the immune response by blocking the OX40-OX40 ligand interaction alleviates the
symptoms of influenza, without affecting the ability to clear the virus, is very
exciting. This new research suggests that the down-regulation of OX40 signaling
could play an important role in the fight against the symptoms of influenza and
perhaps other diseases similarly characterised by excessive immune response'.

Xenova's rights to the OX40 technology include rights relating to the
up-regulation of the immune system which may be used for the development of
novel treatments for cancer and infectious disease.  Xenova's rights to
down-regulate the immune system have been the subject of development and licence
agreements entered into with Celltech and Genentech.

The full text of the Imperial announcement follows overleaf:

                                    - ends -


UK:                                               US:
Xenova Group plc                                  Trout Group/BMC Communications
Tel: +44 (0)1753 706600                           Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer           Press: Brad Miles (Ext 17) 
                                                  Daniel Budwick (Ext 14)
Daniel Abrams, Group Finance Director             Investors: Jonathan Fassberg 
                                                  (Ext 16) Lee Stern (Ext 22)
Jon Davies, Corporate Communications

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell

Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova has a broad pipeline of
programmes in clinical development.  The Group has a well-established track
record in the identification, development and partnering of innovative products
and technologies and has partnerships with significant pharmaceutical and
biopharmaceutical companies including Lilly, Pfizer, Celltech, Genentech, QLT
and Millennium Pharmaceuticals.

About OX40/OX40L

Inflammation is part of the body's normal response to the presence of infection
or other unwanted foreign material.  In certain circumstances this process can
cause damage to the body's own tissues.  In many cases this pathology is
orchestrated by activated T cells.  Consequently drugs that are capable of
inhibiting the action of these activated T cells have potential as therapeutics
for control of inflammatory disease.

OX40 is a receptor molecule found on the surface of activated T cells at the
site of inflammation and offers an important potential target for development of
a selective inhibitor of inflammation.  Through collaboration and license
agreements with Stanford University, and the Providence Medical Center,
Portland, Xenova has intellectual property covering therapeutic use of the OX40
and OX40 Ligand proteins and their related antibodies.

Xenova has developed a modified form of the OX40 molecule which can be used to
block the interaction between the OX40 receptor and its ligand and hence inhibit
T cell activation.  This product candidate has been shown effective in a
preclinical model of autoimmune disease, and has moved into preclinical

Development of a monoclonal antibody against OX40 presents an alternative
approach to target and destroy OX40-bearing activated T cells and hence treat
autoimmune disease.  This strategy is being pursued by Celltech Group under a
license agreement with Xenova, which began in September 1999.

A development and license agreement worth up to $63m (£43.2m) was signed in
April 2002 with Genentech Inc ('Genentech') for the worldwide rights to develop
and market products, primarily targeting disorders of the immune system, based
on Xenova's OX40 receptor protein and anti-OX40 Ligand antibody programs. Under
this agreement, Xenova retains all rights to the up-regulation of the immune
system using the OX40:OX40L interaction, including for use in oncology and
infectious disease therapy.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialization of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialize products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialization activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

    Imperial researchers show novel flu treatment eliminates symptoms in mice

Imperial College London researchers report today in the Journal of Experimental
Medicine that they have developed a novel strategy for effectively treating the
symptoms of the most deadly type of flu.

Working with influenza A virus, they show in mice that their novel treatment
eliminates symptoms by reducing the response of active T white blood cells by a

Flu A is the type of influenza responsible for pandemics such as the 1919
outbreak of 'Spanish flu', which globally killed more than 20 million people.

Unlike current attempts to prevent or treat flu, which rely on either yearly
vaccinations that try to predict how the virus might mutate, or anti viral drugs
that must be administered as soon as there is contact with the virus, this new
treatment can be given after symptoms present.

Dr Tracy Hussell of Imperial's Centre for Molecular Microbiology and Infection
and senior author of the paper says: 'Three times in recent history the flu
virus has evolved from a disease characterised by coughs and sneezes to a world
killer. The recent SARS epidemic highlights how quickly a deadly virus can
spread in modern society and we are long overdue for the next flu pandemic. The
sobering reality is that influenza is one of the grand masters at evading human
immune response.

'During flu infection the immune system has an 'all hands on deck' attitude to
the viral assault. But it's this that causes most of the damage. The exaggerated
immune response produces inflammatory molecules that lead to what's known as a
'cytokine storm'. Essentially too many cells clog up the airways and prevent
efficient transfer of oxygen into the bloodstream.

'By selectively reducing this cellular load we've shown it's possible to
eliminate clinical symptoms whilst effectively tackling and clearing the

The body has two major classes of white blood cells, T and B lymphocytes. While
B cells produce tailor-made antibodies that help the body remember and quickly
respond to invaders, T cells patrol the body, seek out and destroy diseased
cells. But the T cell response also produces inflammatory mediators that lead to
the 'cytokine storm'.

Until now, treatments to eliminate the cytokine storm have focused on inhibiting
all T cells. But this leaves the patient unable to clear the virus and
susceptible to other infections. Dr Hussell's team have developed a way of down
regulating a molecule known as OX40 that only targets T cells that have recently
been alerted to the presence of the flu virus.

'OX40 sends out a 'survival signal' instructing activated T cells to remain in
the lungs for longer to help fight the infection. However, because new cells are
arriving all the time this prolonged presence is not needed,' explains lead
researcher Ian Humphreys of Imperial's Centre for Molecular Microbiology and

'Inhibiting this signal therefore allows T cells to vacate the lungs earlier
whilst leaving behind a sufficient immune presence.'

Using a fusion protein OX40:Ig supplied by the pharmaceutical company Xenova
Research, the scientists were able to demonstrate that OX40:Ig blocks active T

Results show six days after infection with flu, mice treated with OX40:Ig were
indistinguishable from uninfected control mice. But infected mice that had not
been treated lost 25 per cent of their body weight, appeared hunched, withdrawn
and lost their appetite - all characteristic symptoms of flu.

When treatment with OX40:Ig was delayed for several days after infection, until
the mice had lost 20 per cent of their body weight and OX40:Ig was administered,
symptoms were reversed.

Re-infection also indicated that the ability of mice to respond to a second
infection was not affected by the reduced T cell immunity during the initial

Dr Hussell added: 'There is tremendous scope for this treatment. Basically any
disease that is characterised by an excessive T cell inflammatory response,
whether in the lungs, in the case of Bronchitis, Asthma and Pneumonia, or in the
joints, such as Rheumatoid arthritis, could be a candidate for this type of
treatment.  If the clinical symptoms of SARS are caused by excessive immune
responses it too could be effectively treated.'


For further information, please contact:

Judith H Moore
Imperial College London Press Office
Tel: +44 (0)20 7594 6702
Mobile: +44 (0)7803 886 248
E-mail: [email protected] 

Notes to editor
Journal: Journal of Experimental Medicine

Title: 'A critical role for OX40 in T Cell mediated immunopathology during lung
viral infection'

Authors: Humphreys, Ian R (1); Walzl, Gerhard (1); Edwards, Lorna (1); Rae,
Aaron (1); Hill, Sue (2); Hussell, Tracy (1).

(1) Imperial College London, Exhibition Road, London SW7 2AZ, UK
(2) Xenova Research Ltd, 310 Cambridge Science Park, CB4 0WG

Facts about flu

There are three main types of influenza virus A, B and C. Of these, A and B are
of most concern because of the way in which their genomes evolve.

The organisation and type of genetic material flu virus is made from helps it
hide from the immune system. RNA viruses, such as flu have a higher mutation
rate because they don't proof check their genetic material when they make new
viral particles. As a result, there's a huge amount of genetic variability
within a new generation of virus particles. Although many of the mutation will
be detrimental there will be enough that are able exploit a weakness in the
immune system.

Influenza A is particularly dangerous because it readily undergoes 'gene
swapping' or reassortment. This means two strains of the virus can infect the
same cell and swap genetic information. Add this to influenza's ability to
infect certain animals and birds, and you have a situation where two very
distinct strains can infect a cell and hybridise to create a new strain that is
very different from anything the immune system has encountered before. It is
this process of gene swapping that has been linked with the emergence of most

About Imperial College London

Consistently rated in the top three UK university institutions, Imperial College
London is a world leading science-based university whose reputation for
excellence in teaching and research attracts students (10,000) and staff (5,000)
of the highest international quality.

Innovative research at the College explores the interface between science,
medicine, engineering and management and delivers practical solutions that
enhance the quality of life and the environment - underpinned by a dynamic
enterprise culture.



This email contains confidential information and may be otherwise protected by
law.  Its content should not be disclosed and it should not be given or copied
to anyone other than the person(s) named or referenced above.  If you have
received this email in error, please contact the sender.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                      

a d v e r t i s e m e n t